Pneumonia is one of the most common causes of pneumonia in children around the world, and it leads to the death of children. Yes, but now the vaccine has come for it, and this vaccine will save the lives of babies from deadly diseases like pneumonia. Yes, Hyderabad-based vaccine maker Biological E Ltd. on Thursday announced that the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has reviewed and approved clinical trial data of Phase III infants.

Let us tell you that this company is recommended for the manufacture of its 14-valent pediatric medicine. Yes, it is being said that single dose and multi dose of vaccine have been allowed to make vaccines against pneumoniae infection. At the same time, the company said that the PCV14 vaccine can be given to babies at the age of 6, 10 and 14 weeks. Let us tell you that according to Biological E, Streptococcus pneumoniae infection remains a leading cause of death in children under 5 years of age in India and developing countries. Yes, and with the PCV14 vaccine, Biologicals E hopes to contribute to the prevention of aggressive pneumococcal disease and protect millions of children from the disease globally.

Mahima Datla, Managing Director, Biologicals E Ltd. said, “We are delighted with this remarkable development. BE's PCV14 will protect millions of infants worldwide and contribute to the prevention of invasive pneumococcal disease. This recommendation of the SEC and DCGI, with anticipated formal approval from the government, will be another important life-saving vaccine for pediatric use in India. Biologicals E Ltd. will also work with WHO and other global regulatory agencies to make this vaccine available globally."

Also note that PCV14 has 14 serotypes, 12 of which are identical to Prevnar13 from Pfizer (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). In addition, PCV14 has 2 more serotypes 22F and 33F, for which cases of infection are increasing globally. In addition, two pneumococcal conjugate vaccines Prevnar13 and Merck's VAXNEUVANCE are currently approved globally in terms of serotype coverage for PCV14 infants.

Alert issued in Meghalaya over 'Jihad,' activities seen on Bangladesh border

Modi hands over first indigenous aircraft carrier INS Vikrant to Navy, Know everything about it

Terrorist attacks on migrants continue in Kashmir, now another worker shot by terrorist